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INTRODUCTION
Foot and ankle pain is common, with an estimated point prev-
alence of 20% (1). For adults aged older than 55, the foot/ankle 
is the third most common site of self- reported joint pain, following 
the knee and the hand/wrist (2). In a rheumatology setting, 64% to 
93% of patients with inflammatory arthritis self- report experienc-
ing foot pain that is moderate to severe (3–5), and patients with 
rheumatoid arthritis whose debut joint is a foot/ankle joint expe-
rience higher disease activity, higher disability, and lower quality 
of life (6). Given the common presentation and significant impact 
of musculoskeletal symptoms involving the foot and ankle, valid 
and reliable patient- reported outcome measures can improve 
assessment and management. The aim of this review was to pro-
vide an overview of the most common outcome measures used 
to evaluate foot pain, foot function, and general foot health for 
adults with musculoskeletal symptoms of the foot and ankle. Spe-
cific objectives were to demonstrate the practical application of 
each outcome measure, to describe the psychometrics of each 
instrument, and to provide a critical appraisal of each instrument 
to the rheumatology community.
To identify outcome measures for inclusion, we used a 
recently published systematic review of patient- reported out-
come measures for foot and ankle conditions (7). Outcome meas-
ures were eligible if they evaluated the foot or foot and ankle (but 
not the ankle only); evaluated pain, function, or general foot health; 
and evaluated musculoskeletal symptoms. Outcome measures 
were excluded if they evaluated specific conditions (eg, Achilles 
tendinopathy) or were generic pain or function measures (eg, 
visual analog scale [VAS] or 36- Item Short Form Health Survey 
[SF- 36]). Eligible outcome measures were ranked based on how 
frequently they have been used over the past 10 years. To deter-
mine the rank, we searched the title of the outcome measure in 
PubMed and Google Scholar and used the number of times the 
original article describing the outcome measure had been cited. 
This information is provided in the Supplementary Material.
The 10 most frequently used outcome measures over the 
past 10 years are the American Orthopaedic Foot and Ankle 
Society (AOFAS) Clinical Rating Scales, the Foot and Ankle Abil-
ity Measure (FAAM), the Foot and Ankle Outcome Score (FAOS), 
the Foot Function Index–Revised (FFI- R), the Foot Health Status 
Questionnaire (FHSQ), the Leeds Foot Impact Scale for Rheu-
matoid Arthritis (LFIS- RA), the Manchester Foot Pain and Disa-
bility Index (MFPDI), the Manchester- Oxford Foot Questionnaire 
(MOXFQ), the Self- Reported Foot and Ankle Score (SEFAS), and 
the Visual Analog Scale–Foot and Ankle (VAS- FA).
AMERICAN ORTHOPAEDIC FOOT AND ANKLE 
SOCIETY CLINICAL RATING SCALES: ANKLE/
HINDFOOT (AOFAS- AH), MIDFOOT (AOFAS- M), 
HALLUX (AOFAS- HJ), AND LESSER (AOFAS- LJ)
Description
Purpose. To provide a standardized method of reporting the 
clinical status of the foot and ankle (8).
Content or domains. The AOFAS Clinical Rating Scales are 
four separate outcome measures that evaluate different anatomic 
regions of the foot and ankle: the ankle/hindfoot (AOFAS- AH), 
the midfoot (AOFAS- M), the hallux metatarsophalangeal- 
interphalangeal (AOFAS- HJ), and the lesser metatarsophalangeal- 
interphalangeal (AOFAS- LJ). Each outcome measure evaluates 
pain (one item), function (five to seven items) and alignment 
(one item).
Number of items. AOFAS- AH: nine items; AOFAS- M: 
seven items; AOFAS- HJ: eight items; and AOFAS- LJ: eight items.
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Response options/scale. A combination of subjective 
patient- reported items that are scored by using 3- or 4- point Lik-
ert scales and clinician- led objective measures that are scored by 
using 2- to 3- point Likert scales.
Recall period for items. Unspecified.
Cost to use. Free.
How to obtain. Each outcome measure is described in the 
original article (8). An online calculator is also available at www.
ortho toolk it.com.
Practical application
Method of administration. Patient and clinician adminis-
tered with paper and pencil.
Scoring. Each item is scored from 0 (representing the worst 
foot status) to scores that range from 5 to 40, depending on the 
item (representing the best foot status). The items are summed to 
give a total score of 100.
Score interpretation. Total scores range from 0 (repre-
senting the worst foot status) to 100 (representing the best foot 
status). Normative data from a sample of 625 people who were 
visitors or employees of a hospital in Germany have been pub-
lished (9).
Respondent time to complete. Five minutes.
Administrative burden. Calculation of the total score 
takes less than 1 minute per participant. The clinician is required 
to perform a joint range of motion assessment and observational 
gait analysis.
Translations/adaptations. The AOFAS- AH has been 
translated and culturally adapted into Dutch (10), German (11), 
Italian (12), Persian (13,14), Portuguese (15), and Turkish (16).
Psychometric information
Floor and ceiling effects. No floor or ceiling effects were 
observed for the AOFAS- AH in people with an acute ankle sprain 
(17) or for people with any foot or ankle condition (13,18,19). A 
ceiling effect was observed for the AOFAS- M in people with Lis-
franc joint injury (20). No floor or ceiling effects were observed for 
the AOFAS- HJ in people with any foot or ankle condition (19). 
Ceiling effects were observed for the AOFAS- LJ in people with 
rheumatoid arthritis and people with no foot or ankle complaints 
(21).
Reliability. The AOFAS published a position statement in 
2011 that outlined the AOFAS Clinical Rating Scales as not reliable 
(22). However, a recent article found moderate internal consist-
ency (Cronbach’s α = 0.75) for the AOFAS- M for 117 people with 
Lisfranc joint injury (20).
Validity. The AOFAS published a position statement in 2011 
that outlined the AOFAS Clinical Rating Scales as not valid (22).
Responsiveness. Responsiveness of the AOFAS Clinical 
Rating Scales (assessed by combining scores from each version 
and reported by using the standardized response mean [SRM] 
and effect sizes) was evaluated in a relatively small sample of 25 
people with a foot or ankle condition that required surgical inter-
vention. An SRM of 1.10 and an effect size of 1.12 suggest an 
acceptable responsiveness to change (23). Acceptable respon-
siveness to change was reported for the AOFAS- AH in a larger 
sample of 117 patients who underwent surgery for ankle arthritis 
(SRM 1.34; effect size 1.69) (24) and for 91 people with hallux val-
gus (area under the receiver operating characteristic [ROC] curve 
of all scales ranged between 0.80 and 0.87) (25).
Minimally important differences. Minimally important 
differences have been determined from a sample of 446 patients 
who underwent hallux valgus surgery. These scores ranged from 
7.9 to 30.2, depending on the method of calculation (26).
Generalizability. The AOFAS Clinical Rating Scales are 
the most frequently used outcome measures in orthopedic set-
tings (27,28). However, it is difficult to determine whether this 
questionnaire is generalizable to other populations because the 
scales are not reliable or valid (22).
Use in clinical trials. The AOFAS Clinical Rating Scales 
are among the most frequently used outcome measures in foot 
and ankle research (29), despite recommendations against their 
use. The questionnaires have been used as outcome measures 
of clinical trials evaluating rheumatoid arthritis (30), ankle arthritis 
(31), ankle sprain (32), tibial fracture (33), ankle fracture (34), cal-
caneal fracture (35), Lisfranc injury (36), metatarsal fracture (37), 
Achilles tendinopathy (38), plantar fasciitis (39), and hallux valgus 
(40–43).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The AOFAS Clinical Rating Scales are individ-
ualized to different anatomical regions of the foot and ankle. The 
AOFAS- AH is responsive for certain conditions. The AOFAS Clin-
ical Rating Scales are easy to administer and score and can be 
performed quickly in a clinical setting.
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Caveats and cautions. The AOFAS Clinical Rating Scales 
are not reliable or valid, and the use of these scales is discouraged 
by the AOFAS (22).
Clinical usability. The use of the AOFAS Clinical Rating 
Scales in clinical practice should be discouraged, despite the ease 
of use of these questionnaires.
Research usability. The use of the AOFAS Clinical Rating 
Scales in a research setting should be discouraged because of 
the lack of reliability and validity (22). Furthermore, it has been sug-
gested that these scales produce a skewed distribution, and the 
interpretation of research findings based on the AOFAS Clinical 
Rating Scales should be regarded with caution (44).
FOOT AND ANKLE ABILITY MEASURE
Description
Purpose. To evaluate changes in self- reported physical 
function for individuals with leg, ankle, and foot musculoskeletal 
conditions (45).
Content or domains. The FAAM evaluates two domains: 
activities of daily living (21 items) and sports (6 items).
Number of items. Twenty- nine items.
Response options/scale. Five- point Likert scales.
Recall period for items. One week.
Cost to use. Free.
How to obtain. The formatted questionnaire can be down-
loaded from https://www.aaos.org/quality/research-resources/
patient-reported-outcome-measures/lower-extremity-perfor 
mance-measures/. An online calculator is also available at www.
ortho toolk it.com/faam.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 (“unable to do”) to 4 
(“no difficulty”). An “N/A” option is available for each item, and if 
this option is selected, the item is excluded from the total score. 
The activities of daily living subscale and the sports subscale are 
scored separately. The total score is calculated by dividing the 
summed score by the maximum possible score (ie, for the activ-
ities of daily living subscale, if all items are answered, a summed 
score of 60 would be divided by 84. If one item was marked “N/A,” 
the summed score of 60 would be divided by 80). This figure is 
then multiplied by 100 and reported as a percentage (45).
Score interpretation. Subscale scores range from 0 (rep-
resenting the worst physical function) to 100 (representing the best 
physical function). Normative data from a sample of 271 people 
from the general population in the United States have been pub-
lished in a conference abstract (46). The average FAAM activities 
of daily living subscale score was 92.3 (SD 12.3), and the average 
FAAM sports subscale score was 85.1 (SD 20.2).
Respondent time to complete. Five to 10 minutes.
Administrative burden. Self- study of the scoring docu-
mentation (45).
Translations/adaptations. The FAAM has been trans-
lated and culturally adapted into Brazilian Portuguese (47), Chi-
nese (48), German (49), Italian (50), Japanese (51), Spanish (52), 
and Turkish (53). Translation without cultural adaptation has been 
performed for Dutch (54), French (55), Persian (56), and Thai (57).
Psychometric information
Floor and ceiling effects. No floor or ceiling effects were found 
in the original study, which has also been reported for translations of 
the FAAM in Turkish, Dutch, and Persian (45,53,54,56). One study that 
evaluated the responsiveness of the FAAM in a sample of participants 
with diabetes found a floor effect for the sports subscale (58).
Reliability. For the activities of daily living subscale, internal 
consistency (Cronbach’s α) in the original study of 164 patients with 
a new leg, ankle, or foot musculoskeletal condition was 0.98, and 
for 79 patients with an existing leg, ankle, or foot musculoskeletal 
condition, it was 0.96. For the sports subscale, Cronbach’s α was 
calculated for new and existing patients combined and was 0.98 
(45). Similar internal consistency (by using the Rasch measure-
ment model) was observed for the activities of daily living subscale 
(0.87) and the sports subscale (0.89) in a study of 456 patients who 
underwent surgery for an ankle injury (59). Test- retest reliability (intr-
aclass correlation coefficients) for 79 patients with an existing leg, 
ankle, or foot musculoskeletal condition was 0.89 for the activities 
of daily living subscale and 0.87 for the sports subscale (45).
Validity. Content validity was demonstrated in the original 
publication by using item response theory and an evaluation of 
individual items by expert clinicians. Criterion validity has not been 
evaluated because of the absence of a gold standard measure of 
foot function. Construct validity has been demonstrated by the 
observation of high associations (Pearson’s r) between the FAAM 
subscales and the SF- 36 physical function subscale (activities of 
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daily living subscale: 0.84; sports subscale: 0.78) (45) and the 
12- Item Short Form Health Survey physical components sub-
scale (activities of daily living subscale: 0.83; sports subscale: 
0.78) (59). In patients with hallux valgus, a high association was 
observed between the FAAM activities of daily living subscale and 
the Patient- Reported Outcomes Measurement Information Sys-
tem physical function scale (0.70) (60).
Responsiveness. Responsiveness (assessed by using mean 
differences, Guyatt Index, and area under the ROC curves) was eval-
uated in the original publication for a sample of participants (N = 164) 
with leg, ankle, and foot pain. Adequate responsiveness was found for 
the FAAM activities of daily living subscale (mean difference: 17.1 [SD 
19.8]; Guyatt Index: 2.75; ROC: 0.80) and the sports subscale (mean 
difference: 17.2 [SD 24.8]; Guyatt Index: 1.40; ROC: 0.72) (45). In a 
sample of participants with diabetes and a foot or ankle orthopedic 
condition, responsiveness was evaluated at a group level (by using 
analysis of variance) and an individual level (by using area under the 
ROC curves) for the FAAM activities of daily living subscale. Similar 
responsiveness to the original publication was observed (mean differ-
ence: 17.0 [SD 19.0]; ROC: 0.73) (58). Adequate responsiveness was 
reported for the Turkish versions of the FAAM (effect size: 1.40) (53).
Minimally important differences. Minimally important 
differences have been reported from a sample of participants with 
lower- limb musculoskeletal conditions (activities of daily living sub-
scale: 8 points; sports subscale: 9 points) (45), those with dia-
betes (9 points) (58), and those attending a university orthopedic 
clinic (activities of daily living subscale: range between 3 and 25 
points; sports subscale: range between 9 and 77 points, depend-
ing on the method of calculation) (61).
Generalizability. The FAAM was originally developed for 
use in patients with a musculoskeletal condition of the leg, ankle, 
or foot and is therefore generalizable to a variety of patient groups 
and conditions. Psychometric properties have been evaluated 
in both surgical and nonsurgical samples. However, the sports 
subscale may not be relevant for some patient populations, as 
demonstrated by the floor effect in patients with diabetes (58).
Use in clinical trials. The FAAM has been used as an out-
come measure in clinical trials of ankle injuries (62–64), plantar 
heel pain (65–68), taping for exercise- related leg pain (69), and 
edema in patients with ankle/hindfoot fractures (70).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the FAAM are its availability in 
several languages, its extensive psychometric evaluation (includ-
ing Rasch analysis) in both surgical and nonsurgical samples, and 
its simple administration and scoring.
Caveats and cautions. The use of the FAAM with certain 
patient groups should be considered. Rasch measurement mod-
eling identified that the FAAM activities of daily living subscale 
items 10 (coming up on your toes) and 11 (squatting) may not 
be appropriate to evaluate ankle ability and that the wording may 
need revision (59). Also, a floor effect was identified for the sports 
subscale in patients with diabetes (58).
Clinical usability. The FAAM is a feasible outcome meas-
ure to evaluate physical function in patients with conditions 
affecting the leg, ankle, and foot. The American Physical Ther-
apy Association recommends that the FAAM to be used by 
clinicians to evaluate treatment for plantar heel pain (71). A con-
sensus statement from the International Ankle Consortium rec-
ommended that the FAAM be used to evaluate the efficacy of 
treatments after acute ankle sprain (72).
Research usability. The FAAM is a robust outcome meas-
ure to evaluate physical function in patients with conditions affect-
ing the leg, ankle, and foot. The minimally important differences 
vary depending on the method of calculation, which may impact 
the interpretation of findings.
FOOT AND ANKLE OUTCOME SCORE
Description
Purpose. The FAOS is an adaptation of the Knee Injury and 
Osteoarthritis Outcome Score, which was originally developed in 
1998 to assess short- and long- term patient- relevant outcomes 
following knee injury (73). In 2001, Roos et  al (74) substituted 
“knee” with “foot/ankle” and validated the new tool in 213 in 
patients undergoing surgical reconstruction of lateral ankle liga-
ments. The FAOS has primarily been used as a foot and ankle 
surgical outcome measure.
Content or domains. The FAOS has five foot- health–
related domains: pain (9 items), other symptoms (7 items), activ-
ities of daily living (17 items), sport and recreational activities (5 
items), and foot and ankle- related quality of life (4 items).
Number of items. Forty- two items.
Response options/scale. Five- point Likert scale 
(no, mild, moderate, severe, and extreme).
Recall period for items. One week.
Cost to use. Free.
How to obtain. The formatted questionnaire and user’s 
guide can be downloaded from www.koos.nu. An online calcula-
tor is also available at www.ortho toolk it.com/faos.
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Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 to 4. Raw subscale 
scores are calculated first by adding each item, and then each 
subscale is converted to a metric from 0 to 100, in which 100 
denotes the most severe condition.
Score interpretation. Subscale scores range from 0 
(representing optimal foot health) to 100 (representing worst foot 
health). Higher scores therefore represent worse foot health (74). 
There are no published normative data.
Respondent time to complete. Ten minutes.
Administrative burden. Calculation of subscale scores 
takes less than 5 minutes per participant.
Translations/adaptations. The FOAS has been trans-
lated into Chinese (75), Danish (76), Dutch (77), German (78), 
Korean (79), Persian (80), Thai (81), and Turkish (82). Arabic, 
Estonian, Finnish, Norwegian, Polish, Portuguese, Brazilian Portu-
guese, Spanish, and Swedish versions are available at www.koos.
nu, although validation is still in progress.
Psychometric information
Floor and ceiling effects. In the original study (74), no floor 
effects were observed, although ceiling effects were evident for the 
pain (34% of patients recording the highest possible score), other 
symptoms (24%), activities of daily living (44%), sport and recrea-
tion (30%), and quality of life (19%) subscales. Ceiling effects were 
also observed in a study of 136 patients undergoing surgery for 
ankle osteoarthritis, in which 29% of patients recorded the highest 
possible score for the sport and recreation subscale (83).
Reliability. Internal consistency (Cronbach’s α) in the 
original study of 213 patients undergoing surgical reconstruc-
tion of lateral ankle ligaments for each subscale was as follows: 
pain, 0.94; other symptoms, 0.88; activities of daily living, 0.97; 
sport and recreation, 0.94; and quality of life, 0.92 (74). Sub-
sequent studies have reported similar findings regarding pain 
(0.81- 0.96), activities of daily living (0.88- 0.97) and sport and 
recreation (0.79- 0.96), although internal consistency is generally 
lower for other symptoms (0.39- 0.86) and quality of life (0.62- 
0.91) (75,79–85).
Test- retest reliability (intraclass correlation coefficients) over 
a 30- day period in 38 patients from the original study was as fol-
lows: pain, 0.78; other symptoms, 0.86; activities of daily living, 
0.70; sport and recreation, 0.85; and quality of life, 0.92 (74). Sub-
sequent studies have reported similarly high test- retest reliability 
for pain (0.76- 0.97), other symptoms (0.63- 0.96), activities of daily 
living (0.70- 0.99), sport and recreation (0.68- 0.99) and quality of 
life (0.70- 0.99) (75–77,79,80,82,84,85).
Validity. Content validity was originally examined by ask-
ing patients to rate the relevance and importance of each item 
on a scale of 1 to 3 and to suggest additional items. All items 
had a mean relevance score above 2.0, and no other items were 
suggested (74). Criterion validity has not been evaluated because 
of the absence of a gold standard measure of foot pain or func-
tion. Construct validity has been demonstrated by the observation 
of moderate associations (Spearman’s ρ or Pearson’s r) between 
FAOS subscale scores and the Karlsson score (0.58- 0.67) (74), 
the Western Ontario and McMaster Universities Osteoarthritis 
Index (pain, 0.49; other symptoms, 0.37; activities of daily living, 
0.52; sport and recreation, 0.45) (84), the AOFAS score (pain, 
0.49; other symptoms, 0.30; activities of daily living, 0.40; sport 
and recreation, 0.43; quality of life, 0.45) (77), the numerical rat-
ing scale for pain (pain, 0.98; other symptoms, 0.63; activities of 
daily living, 0.89; sport and recreation, 0.74; quality of life, 0.66) 
(75), the visual analog pain scale (pain, 0.66- 68; other symptoms, 
0.45- 0.46; activities of daily living, 0.53- 0.62; sport and recrea-
tion 0.46- 0.58; quality of life, 0.50- 0.63) (77,79), and the SF- 36 
physical function (pain, 0.37- 0.72; other symptoms, 0.12- 0.73; 
activities of daily living, 0.46- 0.77; sport and recreation, 0.21- 079; 
quality of life, 0.09- 0.71) (75,77,80–83,85,86), role physical (pain, 
0.28- 0.62; other symptoms, 0.02- 0.59; activities of daily living, 
0.24- 0.64; sport and recreation, 0.18- 0.57; quality of life, 0.05- 
0.72) (75,77,80,81,83,85,86), and bodily pain subscales (pain, 
0.26- 0.78; other symptoms, 0.08- 0.71; activities of daily living, 
0.24- 0.75; sport and recreation, 0.18- 0.67; quality of life, 0.10- 
0.76) (75,77,80–83,85,86). Generally, the construct validity has 
been reported to be lower for the other symptoms and quality of 
life subscales.
Responsiveness. Responsiveness (effect size) in patients 
undergoing hindfoot/ankle surgery and surgery for ankle osteo-
arthritis, hallux valgus, and flatfoot deformity has been shown to 
be moderate to high for the pain (0.51- 1.06) and quality of life 
(0.90- 1.58) subscales and low to high for the activities of daily 
living (0.27- 0.87), other symptoms (0.12- 0.55), and sport and rec-
reation (0.01- 1.02) subscales (83,85–87).
Minimally important differences. Minimally important 
differences for the Dutch version of the FAOS (by using two differ-
ent anchor methods) were reported as follows: pain, 7/13 points; 
other symptoms, 15/13 points; activities of daily living, 18/14 
points; sport and recreation, 23/33 points; and quality of life, 
22/22 points. However, these values varied according to base-
line scores and had large confidence intervals, indicative of poor 
reliability (87).
MEASURES OF FOOT PAIN, FUNCTION, AND GENERAL HEALTH |      299
Generalizability. Although the FOAS has been evaluated 
in a variety of patient groups and conditions, it has primarily been 
used in surgical studies. Its psychometric properties in nonsurgi-
cal studies are relatively limited.
Use in clinical trials. The FAOS has been used as the 
primary outcome measure in randomized trials of rehabilitation 
(88–90) and surgical repair (91–93) after ankle sprain and in ran-
domized trials of laser treatment (94) and bracing (95) for Achilles 
tendinopathy.
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the FAOS include its broad cov-
erage of five distinct domains of foot health and its availability in 
several languages.
Caveats and cautions. The FAOS items were derived from 
a knee outcome score rather than being specifically developed for 
the foot. This is particularly evident in items 4 (“Can you straighten 
your foot/ankle fully?”) and 5 (“Can you bend your foot/ankle fully?”) 
which are appropriate for the knee but have questionable applica-
bility to the foot. The other symptoms, sports and recreation, and 
quality of life subscales do not perform as well as the pain and activ-
ities of daily living scales in terms of internal consistency, construct 
validity, and responsiveness. Ceiling effects have been observed for 
each subscale, and minimal important differences vary according to 
baseline scores and have large confidence intervals. A Rasch anal-
ysis has not yet been performed on the FAOS, so it is unclear as 
to whether the overall subscale scores summed from each ordinal 
item can be considered linear, interval- level variables (96).
Clinical usability. The FAOS is relatively long compared 
with other scales (42 items) and may therefore be too burden-
some for routine clinical use. An evaluation of the Korean version 
demonstrated that paper and electronic (tablet) formats provided 
equivalent results, although patients found the electronic version 
easier to complete (97).
Research usability. The FAOS was the second most 
commonly used outcome measure in 2015- 2016 (98). However, 
because of several psychometric shortcomings, particularly ceil-
ing effects and the absence of robust minimally important dif-
ference values and Rasch analysis, further development of this 
outcome measure is required before it can be recommended for 
use in clinical trials.
FOOT FUNCTION INDEX–REVISED
Description
Purpose. To evaluate foot- health–related quality of life.
Content or domains. The Foot Function Index (FFI) was 
developed in 1991 to measure the impact of foot pathology on 
function in terms of pain, disability, and activity restriction (99). In 
2006, the FFI was revised (FFI- R) to evaluate four domains: pain 
and stiffness (20 items), difficulty (20 items), activity limitation (9 
items), and social/emotional issues (19 items) (100).
Number of items. There are two versions of the FFI- R, a 
short and long form. The short form contains 34 items, and the 
long form contains 68 items.
Response options/scale. The FFI- R uses a 4- point Likert 
scale from 1 (“no pain,” “no stiffness,” “no difficulty,” and “none of 
the time”) to 4 (“severe pain,” “severe stiffness,” “severe difficulty,” 
“all of the time,” and “most of the time”). A score of 5 can be 
selected for items that are not applicable. The original version of 
the FFI- R used a 6- point Likert scale (100), but this was revised to 
the current 4- point scale in 2013 (101).
Recall period for items. One week.
Cost to use. Free.
How to obtain. The formatted FFI- R short and long forms 
are available in a review article (101).
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Scores for each subscale are summed then divided 
by the maximum total score for the subscale items that the patient 
indicated were applicable, after which they are multiplied by 100 and 
reported as a percentage. The pain and stiffness subscale scores 
should be combined and reported as a single pain/stiffness score, 
despite the outcome measure indicating that each subscale has 
an individual score. The scoring of pain and stiffness as separate 
subscales was revised during the development of the FFI- R (100).
Score interpretation. Scores range from 0%- 100%, with 
higher scores representing a worse foot function. The long form 
FFI- R can be used to obtain a total score and individual subscale 
scores. The short form FFI- R was developed to obtain a total foot 
function score (100). Normative data have been derived from the 
German version of the FFI but not from the FFI- R (102).
Respondent time to complete. Less than 30 minutes for 
the long form and 10 minutes for the short form.
Administrative burden. Self- study of the scoring docu-
mentation (101).
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Translations/adaptations. The original FFI was revised in 
2006 to the FFI- R. The FFI- R has been adapted to a short form 
(34 items) and a long form (68 items). The FFI- R has been trans-
lated and culturally adapted into Brazilian Portuguese (103), Polish 
(104), and Turkish (105).
Psychometric information
Floor and ceiling effects. A floor effect was demonstrated 
for 4.5% of the sample used to develop the FFI- R (100).
Reliability. Internal consistency was analyzed in the original 
study of 92 patients from a foot arthritis clinic at a Veterans Health 
Administration hospital. A Rasch analysis of the FFI- R total score 
found a person reliability of 0.96 and an item reliability of 0.93. 
The item reliabilities for the subscales were as follows: pain and 
stiffness, 0.93; disability, 0.92; activity limitation, 0.90; and social/
emotional issues, 0.84 (100). For the short form FFI- R, the person 
reliability was 0.95, which suggests the total score of the short 
form FFI- R is similar to the total score for the long form FFI- R. The 
test- retest reliability has not been determined for the FFI- R.
Validity. Content validity of the FFI- R was evaluated by 
using the original FFI, a literature review, interviews with foot spe-
cialists, reviews by foot specialists in a focus group, interviews 
with patients about their experiences, and reactions to completing 
a draft of the FFI- R (100). Criterion validity has not been evaluated 
because of the absence of a gold standard measure of foot pain 
or function. Construct validity has been evaluated by using Rasch 
item maps and the correlation with the time taken to walk 50 ft. 
Rasch item maps found that items of low- severity foot problems 
(eg, standing on tip toes) were found at the bottom (low disabil-
ity) of the item hierarchy. Conversely, items of high severity (eg, 
being bed- bound) were found at the top (high disability) of the item 
hierarchy. Construct validity was also evaluated by correlating the 
FFI- R with a timed 50- ft walk, and a small to moderate correlation 
of 0.31 (P = 0.018) was found (100).
Responsiveness. Responsiveness of the FFI- R was not 
reported in the original article (100). The responsiveness of the 
FFI- R short form (assessed by using Guyatt Index and the SRM) 
was evaluated in a sample of 88 people with first metatarsophalan-
geal joint osteoarthritis (106). The authors reported responsiveness 
by subscale and found that responsiveness ranged from medium 
to very large depending on the method. Responsiveness for each 
subscale is as follows: pain, SRM of 1.05 and Guyatt Index of 
1.73; stiffness, SRM of 0.68 and Guyatt Index of 1.17; and dif-
ficulty, SRM of 0.70 and Guyatt Index of 1.42. The sensitivity to 
change (minimal detectable change) of the FFI- R long form was 
reported in a study that included 30 participants with midfoot pain 
who were evaluated after the use of foot orthoses for 4 weeks 
(107). The changes for each subscale were as follows: pain, 5 
points; stiffness, 6 points; disability, 7 points; activity limitation, 7 
points; social/emotional issues, 7 points; and total score, 5 points.
Minimally important differences. Minimally important 
differences have not been reported for the FFI- R. As discussed 
in the section above, the minimal detectable change has been 
reported in a study that included 30 participants with midfoot pain 
(107).
Generalizability. The FFI- R was developed with patients 
who were predominantly middle- aged (mean of 69 years) men 
with foot arthritis (100). The questionnaire has also been used as 
an outcome measure for surgical studies (108,109).
Use in clinical trials. The FFI- R has been used as an out-
come measure in clinical trials of medial knee osteoarthritis (110), 
first metatarsophalangeal joint osteoarthritis (111), plantar fasciitis 
(67,112,113), and diabetic foot ulcers (114) and has been used to 
evaluate surgical implants (109).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The FFI- R underwent a robust development by 
using Rasch analysis and classical test theory in combination with 
patient and expert clinician interviews. The outcome measure is 
responsive, is easy to administer and score, and is provided in a 
short form (34 items) if users are interested in a total score rather 
than subscale scores.
Caveats and cautions. The validity and reliability of the 
FFI- R has been evaluated in a relatively small sample (N = 92) 
of predominantly middle- aged men. In addition, the psychometric 
properties of this outcome measure have not been independently 
evaluated. Therefore, independent evaluation in a large diverse 
sample would strengthen the validity and reliability. Regarding 
administration and scoring, studies have differentially scored and 
reported the FFI- R. The original study reported the FFI- R to have 
four subscales (pain and stiffness, difficulty, activity limitation, and 
social/emotional issues); however, several studies have reported 
pain and stiffness as separate scales. Similarly, the original article 
reported that the FFI- R short form should only be used to cal-
culate a total score; however, several studies have reported the 
FFI- R short form by subscale (100).
Clinical usability. The FFI- R is a feasible tool for use in 
clinical practice. The time taken to complete the 68 items of the 
long form FFI- R may be somewhat time consuming during clinical 
encounters. However, a total score can be established by using 
the short form (34 items), which is feasible during clinical encoun-
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ters. The lack of robust clinically important difference values limits 
the interpretability of findings in clinical practice.
Research usability. The methods used to develop the 
FFI- R were robust because of the use of Rasch analysis and 
patient and expert interviews. Accordingly, the FFI- R has been 
used in several randomized trials. However, its psychometric prop-
erties require independent evaluation by using a larger and more 
diverse sample than was used for its development.
FOOT HEALTH STATUS QUESTIONNAIRE
Description
Purpose. The FHSQ was developed in 1998 to measure 
foot- health–related quality of life (115,116).
Content or domains. The FHSQ has four foot- health–
related domains: pain (four items), function (four items), footwear 
(three items), and general foot health (two items).
Number of items. Thirteen items.
Response options/scale. Five- point Likert scales.
Recall period for items. One week.
Cost to use. The current price is $129.95 Australian dollars 
(approximately US $90).
How to obtain. The questionnaire and scoring program are 
available from the CareQuest website at www.fhsq.org.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. There is a dedicated FHSQ software program. 
When less than 50% of the responses for any one scale is miss-
ing, the missing responses are assigned with the average value of 
the completed questions for that scale (116).
Score interpretation. Subscale scores range from 0 (rep-
resenting poorest state of foot health) to 100 (representing optimal 
foot health). Higher scores therefore represent better foot health 
(115,116). There are no published normative data.
Respondent time to complete. Five to 10 minutes.
Administrative burden. Calculation of subscale scores 
by using the software takes less than 5 minutes per participant.
Translations/adaptations. The FHSQ has been trans-
lated and culturally adapted into Brazilian Portuguese (117), 
Danish (118), French (119), Spanish (120), and Valencian (121). 
Turkish, Persian, and Thai versions are also under develop-
ment.
Psychometric information
Floor and ceiling effects. Not reported.
Reliability. Internal consistency (Cronbach’s α) was originally 
reported in 111 podiatry patients as follows: pain, 0.88; function, 
0.86; footwear, 0.85; and general foot health, 0.88 (115). Similar 
internal consistency was observed for the Brazilian Portuguese 
(pain, 0.68; function, 0.81; footwear, 0.82; and general foot health, 
0.76) (117) and French (pain, 0.90; function, 0.90) (119) versions. 
Test- retest reliability (intraclass correlation coefficients) was origi-
nally reported in 72 patients who completed the survey before and 
after a week of routine care: pain, 0.86; function, 0.92; footwear, 
0.74; and general foot health, 0.78 (115), and similar reliability was 
observed by using the French version over a 2- day period (pain, 
0.98; function, 0.96) (119).
Validity. Content validity was demonstrated in the original 
publication by noting that individuals with minor foot complaints 
(such as superficial skin conditions) produced higher scores on 
all FHSQ subscales (indicating better health status) compared 
with individuals with more severe musculoskeletal foot problems 
(115). Similarly, in a study of 784 older people, the FHSQ foot 
function scales were shown to differ between those with minor 
skin or nail problems (mean score 89), structural deformity (mean 
score 78), and acute foot disease (average score 54) (122). Cri-
terion validity has not been evaluated because of the absence 
of a gold standard measure of foot pain or function. Construct 
validity has been demonstrated by the observation of moderate 
associations (Pearson’s r) between FHSQ subscale scores and 
the visual analog pain scale (pain, −0.40 to −0.52; function, 
−0.45 to −0.51) (118,119), numerical rating scale (pain, −0.85; 
function, −0.60) (117), Health Assessment Questionnaire (pain, 
−0.43; function, −0.64) (117), and EuroQOL 5D (pain, −0.45; 
function, −0.58) (120).
Responsiveness. High responsiveness (assessed by using 
Guyatt Index) was reported in a sample of 59 older people who 
received extra- depth footwear to treat their foot pain over a 16- 
week period for the pain (1.70) and function (1.22) subscales, but 
responsiveness of the footwear (0.21) and general foot health 
(0.68) subscales was lower (123). Similarly, in a sample of 88 peo-
ple with first metatarsophalangeal joint osteoarthritis who received 
rocker- sole footwear or foot orthoses over a 12- week period, high 
responsiveness was observed for the pain (1.30) and function 
(1.23) subscales (106).
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Minimally important differences. Minimally important 
differences have been reported in several participant groups, 
including individuals with plantar heel pain (pain, 13 points; func-
tion, 7 points; footwear, 2 points; general foot health, 0 points) 
(124), older people with foot pain (pain, 12 points; function, 10 
points; footwear, 1 point; general foot health, 10 points) (123), and 
individuals with first metatarsophalangeal joint osteoarthritis (pain, 
11 points; function, 10 points) (106).
Generalizability. The FHSQ has broad generalizability 
across a wide range of conditions and participant groups.
Use in clinical trials. The FHSQ has been widely used as 
an outcome measure in clinical trials of treatments for nonspe-
cific foot pain (123,125), plantar heel pain (126–131), first meta-
tarsophalangeal joint osteoarthritis (111,132), interdigital neuroma 
(133), pes cavus (134), and rheumatoid arthritis (135).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the FHSQ include its coverage 
of four distinct domains of foot health (pain, function, footwear, 
and general foot health), its substantial psychometric evaluation, 
its availability in several languages, responsiveness of the pain and 
function subscales, and ease of completion and scoring.
Caveats and cautions. The sample on which the origi-
nal factor analysis was performed was relatively small (N = 225), 
and it has been argued that the factors are not sufficiently dis-
tinct and may therefore contain some redundant items (136). A 
Rasch analysis has not yet been performed on the FHSQ, so it is 
unclear as to whether the overall subscale scores summed from 
each ordinal item can be considered linear, interval- level variables 
(96). The FHSQ footwear and general foot health subscales do not 
appear to perform as well as the pain and function subscales in 
terms of reliability and responsiveness.
Clinical usability. Because of the ease of completion and 
scoring, routine clinical administration of the FHSQ is feasible, and 
it has been used in several audit studies to document patient out-
comes, particularly following foot surgery (137,138). An analysis of 
readability found that the FHSQ is suitable for patients with at least 
seventh- grade reading skills (139).
Research usability. The FHSQ is one of the most com-
monly used outcome measures in randomized clinical trials 
because of its relatively robust psychometric profile, its respon-
siveness, and the availability of minimally important difference val-
ues across a range of foot conditions and patient populations. 
Further investigation is required to evaluate floor and ceiling effects 
and to perform Rasch analysis.
LEEDS FOOT IMPACT SCALE FOR RHEUMATOID 
ARTHRITIS
Description
Purpose. The LFIS- RA was developed in 2005 to evaluate 
the efficacy of multidisciplinary foot-health care in rheumatoid 
arthritis, both for routine clinical purposes and for research (140).
Content or domains. There are two subscales: impair-
ment/footwear (21 items) and activity limitation/participation 
restriction (30 items).
Number of items. Fifty- one items.
Response options/scale. “True” and “not true.”
Recall period for items. At the moment.
Cost to use. Free.
How to obtain. The LFIS- RA can be viewed in an appendix 
to an article describing its translation and cross- cultural validation 
for use in four European languages (141). Users are required to 
register use with the University of Leeds (Leeds, UK) at https://
eprov ide.mapi-trust.org/instr ument s/leeds-foot-impact-scale-for-
rheum atoir-arthr istis.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. A “true” response is scored as 1 point, and a “not 
true” response is scored as 0. Item scores in each subscale are 
then totaled to provide separate subscale scores that can be sum-
mated to provide an overall score (maximum overall score of 51).
Score interpretation. A higher score indicates greater 
disability. A score of greater than 7 on the impairment/footwear 
subscale indicates moderate to high levels of foot impairment, 
and a score greater than 10 on the activity limitation/participation 
restriction subscale indicates moderate to high levels of foot dis-
ability (142).
Respondent time to complete. Not reported.
Administrative burden. Self- study of the scoring docu-
mentation (140).
Translations/adaptations. The LFIS- RA has been trans-
lated and culturally adapted into Dutch, German, and Hungarian 
(141,143).
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Psychometric information
Floor and ceiling effects. No floor or ceiling effects were 
observed for the LFIS- RA in a study of 30 people with rheumatoid 
arthritis (144).
Reliability. Test- retest reliability (intraclass correlation coeffi-
cients) over a 2- week period in the original study was 0.84 for the 
impairment/footwear subscale and 0.96 for the activity limitation/
participation restriction subscale (140).
Validity. Candidate questionnaire items were derived 
from qualitative interviews with patients with rheumatoid arthritis 
and foot problems and then tested by patients with rheumatoid 
arthritis in the presence of an interviewer, ensuring content valid-
ity (140). Selection of the final subscale items was performed by 
fitting them to the Rasch unidimensional measurement model. 
The 21 items in the final impairment/footwear subscale dis-
played a good fit to the Rasch model and no significant devia-
tion from model expectation across the trait (overall mean item 
of −0.25 [SD 1.07], mean person of −0.34 [SD 0.71], and item- 
trait interaction χ2 statistic of 45.07; P = 0.35 [42 degrees of 
freedom]). Similarly, the 30 items in the activity limitation/partic-
ipation restriction subscale had a good fit to the Rasch model, 
with no significant deviation from model expectation (over-
all mean item of −0.38 [SD 0.93], mean person of −0.29 [SD 
0.80], and item- trait interaction χ2 statistic of 64.4; P = 0.18 
[60 degrees of freedom]). Neither scale showed differential item 
function for age, sex,or disease duration. Person separation 
was 0.808 for the impairment/footwear subscale and 0.908 for 
the activity limitation/participation restriction subscale, indicat-
ing the ability to discriminate groups of patients. Furthermore, 
scores for both subscales showed highly significant differences 
between groups of patients categorized into quartiles accord-
ing to their scores for the MFPDI, FFI, and Health Assessment 
Questionnaire. However, the original validation did not include 
strict tests of unidimensionality. In a subsequent adaptation and 
cross- cultural validation study, the original UK version demon-
strated multidimensionality and limited fit to the Rasch model, 
but adaptation satisfactorily resolved these violations of the 
Rasch model (141).
Responsiveness. A study of 30 patients with rheumatoid 
arthritis undergoing foot surgery found that the LFIS- RA was 
less responsive than the FFI (144). Over a mean follow- up of 
38 months, the within- group standard effect size for the LFIS- RA 
was 0.58, the SRM was 0.58, and Guyatt Index was 0.90, indicat-
ing moderate internal responsiveness. In relation to being much 
improved or very much improved on an anchor question about 
change since surgery, the area under the curve within the ROC 
curve was 0.656 and the optimal cutoff point was 1.5 points, with 
a sensitivity of 75% and specificity of 57%.
Minimally important differences. Minimally important 
differences have not been reported for the LFIS- RA.
Generalizability. The LFIS- RA was developed for use in 
rheumatoid arthritis. It has been used in patients with psoriatic 
arthritis (5,145), gout (146–149), and systemic lupus erythemato-
sus (150), although its psychometric properties in conditions other 
than rheumatoid arthritis have not been evaluated.
Use in clinical trials. The LFIS- RA has been used as an 
outcome measure in clinical trials of podiatry care and footwear 
and orthoses interventions in rheumatoid arthritis and gout (151–
153).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the LFIS- RA include its empha-
sis on footwear, its broad coverage of other issues related to foot 
health in rheumatoid arthritis (impairments, activity limitation, and 
participation), and its availability in several languages.
Caveats and cautions. The LFIS- RA was developed for 
use in rheumatoid arthritis. Although it has been used in diseases 
other than rheumatoid arthritis, its psychometric properties for 
these conditions has not been evaluated. There are limited data 
on its responsiveness, and minimal important differences have not 
been reported.
Clinical usability. Although it was designed for use for 
both clinical and research purposes, the LFIS- RA is the second 
longest instrument included in this review and may therefore be 
time consuming to use during clinical encounters. Its interpret-
ability in clinical practice is limited by the lack of robust clinically 
important difference values.
Research usability. The original validation of the LFIS- RA 
suggested that it is valid and reliable. However, further inde-
pendent evaluation of its psychometric properties, including its 
responsiveness, the assessment of minimally important difference 
values, and its performance in diseases other than rheumatoid 
arthritis, is required.
MANCHESTER FOOT PAIN AND DISABILITY 
INDEX
Description
Purpose. The MFPDI was developed in 2000 for use in a 
population survey and aimed to be sufficiently sensitive to identify 
a range of disabilities associated with foot pain (154).
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Content or domains. Its original validation identified 
three domains: pain intensity (5 items), functional limitation (10 
items), and personal appearance (2 items) (154). Two additional 
items about work and leisure activities were excluded from this 
analysis because they were thought not to be relevant to all 
people. Subsequently, independent exploratory factor analyses 
undertaken in separate populations identified different factor 
structures. Menz et al (155) identified four domains: functional 
limitation (seven items), activity restriction (two items), pain 
intensity (six items), and personal appearance (two items). 
Cook et al (156) found two domains: foot and ankle function 
(nine items) and pain and appearance (seven items), with one 
item removed. In a confirmatory factor analysis investigating 
the suitability of these three different factor structures, the orig-
inal three- factor structure performed best (157). Non- English 
language versions have identified further different factor struc-
tures.
Number of items. Nineteen items.
Response options/scale. Items are reported as occurring 
none of the time, on some days, or on most days/every day.
Recall period for items. One month.
Cost to use. The license fee depends on whether the use is 
for a commercial or an academic study, on the number of times 
the measure is to be used, on language requirements, and on 
whether the user manual is required.
How to obtain. The MFPDI can be viewed in an appendix 
to the original article (154). A license to access the questionnaire 
and user manual should be requested from Oxford University 
Innovation at https://innov ation.ox.ac.uk.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. In the original description, it was stated that indi-
vidual subscale (domain) scores could be derived to produce 
an overall disability measure (154), although scoring was not 
described. Various authors have allocated different scores to item 
responses to produce total and individual domain scores: “none 
of the time” = 0 or 1, “on some days” = 1 or 2, and “on most days/
every day” = 2 or 3, so the total score ranges from 0 to 34 or 17 to 
51 depending on which scoring is used (155,156,158,159).
Score interpretation. Higher scores indicate worse foot 
pain/disability. The Rasch unidimensional measurement model 
has shown that the function and pain subscales are unidimen-
sional, and interval- level scores can be obtained (160). A categor-
ical definition of disabling foot pain (present/absent) can also be 
derived. Garrow et al (158) defined disabling foot pain as a prob-
lem occurring on at least 1 of the 17 pain, function, or appear-
ance items on at least some days in the last month. It has been 
argued that this cutoff is too infrequent for “disabling” foot pain, 
which should be defined by using only the functional limitation 
items without the pain intensity and personal appearance items. 
An alternative definition requiring a problem to occur on at least 1 
of the 10 functional limitation items on most days/every day in the 
last month has been validated (157).
Respondent time to complete. Not reported.
Administrative burden. Self- study of the scoring docu-
mentation (154).
Translations/adaptations. The MFPDI has been trans-
lated and culturally adapted into Greek (161), Portuguese (162), 
Spanish (163), Danish (164), Dutch (165), and Chinese (166).
Psychometric information
Floor and ceiling effects. Neither floor nor ceiling effects 
were examined in the original study (154). When using the Dutch 
translation in a clinical trial in people with forefoot problems, 
investigators observed no floor or ceiling effects for the pain and 
function subscales (165). The lowest possible score (0 or 1) was 
scored by 7.4% and 8.8% of participants for the pain and function 
subscales, respectively.
Reliability. Internal consistency (Cronbach’s α) was 0.99 
(19 items) in the original validation (154) and 0.89 (17 items) in the 
subsequent evaluation by Menz et al (155). Cronbach’s α values 
of 0.74, 0.92, and 0.77 have been reported for the pain intensity, 
functional limitation, and appearance domains, respectively (157).
Test- retest repeatability for disabling foot pain was poor for 
pain intensity, fair for functional limitation, and good for appear-
ance (κ = 0.34, 0.57, and 0.61, respectively) when problems were 
required to occur on at least some days in the last month, and 
it was fair for pain intensity (0.55), good for functional limitation 
(0.72), and poor for appearance (0.34) at the more stringent cutoff 
of most days/every day (157).
Validity. Content validity was achieved by interviewing 
patients attending foot clinics about pain, disability, activity limi-
tation, and footwear (154). The proportion reporting disability was 
highest for participants consulting a rheumatologist, followed by 
those consulting their general practitioner and then population 
survey respondents; among the latter, the proportion was higher 
in those who had consulted a health care professional than in 
those who had not, demonstrating construct validity. Criterion 
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validity has not been evaluated because of the absence of a gold 
standard measure of foot pain or function. Construct validity was 
demonstrated subsequently by the observation of lower median 
SF- 36 physical function subscale scores in those reporting prob-
lems in the functional limitations domain (157). Menz et al (155) 
identified associations between disabling foot pain and lower arch 
height, and between disabling foot pain and less ankle joint motion 
as well as correlations (Pearson’s r) between MFPDI scores and 
the Goldberg Anxiety and Depression Scale depression subscale 
(total, 0.34; pain intensity, 0.23; functional limitation, 0.32; appear-
ance, 0.28) and the SF- 36 mental health (functional limitation, 
0.20) and general health (activity limitation, 0.21) subscales.
Responsiveness. Responsiveness (effect size) over 16 
weeks in a randomized trial of extra- depth footwear in Australian 
veterans with persistent, disabling foot pain was small for pain 
(0.21) and functional limitation (0.34) and negligible for personal 
appearance (0.08) (123). In the Dutch translation study, respon-
siveness was moderate, with only one of seven a priori stated 
hypotheses about correlations between change in MFPDI sub-
scales and other foot pain outcome measures being met and with 
correlation with a global perceived effect question not reaching an 
acceptable level (r < 0.5) (165).
Minimally important differences. Only one study has 
attempted to evaluate a minimal important change (MIC) (165). 
However, the MFPDI was not responsive enough to calculate an 
MIC.
Generalizability. The MFPDI was designed for use in a 
population survey. It was developed and validated in people with 
varying foot health profiles attending rheumatology clinics, con-
sulting with their general practitioner, or responding to a postal 
population survey (154). Its psychometric properties have been 
evaluated subsequently in community- dwelling adults across the 
age range (155–157,161), in people consulting with clinical ser-
vices about foot problems (163,164,166), and in participants in 
clinical trials (123,165).
Use in clinical trials. The MFPDI has been used as an out-
come measure in clinical trials in forefoot problems (165), Morton 
neuroma (167,168), plantar callosities/corns (169,170), plantar 
heel pain (171), osteoporosis (172), midfoot osteoarthritis (173), 
and systemic sclerosis (174) and in older people with foot pain or 
foot problems (159,175,176).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the MFPDI include its coverage 
of multiple distinct domains of foot health, its availability in several 
languages, its psychometric evaluation (including Rasch analysis), 
and it being short and easily administered and scored. It is also 
suitable for use in population surveys and can generate both foot 
pain/disability scores and a categorical definition of disabling foot 
pain.
Caveats and cautions. Several different domain struc-
tures have been proposed, and uncertainty remains over 
the most appropriate structure. The original three- factor structure 
is the most commonly used. There has been debate concerning 
the inclusion of foot problems occurring only on some days in 
the categorical definition of disabling foot pain. Its responsiveness 
appears to be limited, and as yet, a minimal important difference 
has not been calculated.
Clinical usability. The MFPDI is short and easily com-
pleted and could be feasible to use in clinical practice. However, 
limited responsiveness and lack of a robust clinically important dif-
ference may impair its interpretability.
Research usability. The MFPDI has been widely used in 
population surveys and is particularly valuable in observational 
studies requiring a case definition for disabling foot pain. Although 
it has been used in several clinical trials, further investigation of 
its responsiveness and minimally important difference values is 
required.
MANCHESTER- OXFORD FOOT QUESTIONNAIRE
Description
Purpose. The MOXFQ is derived from the MFPDI (154) and 
was originally developed in 2006 as an outcome measure for 
hallux valgus surgery (177). It has recently been amended and 
validated for use among patients with a variety of foot or ankle 
problems (178).
Content or domains. The MOXFQ has three foot- 
health–related domains: walking/standing problems (seven 
items), pain (five items), and issues related to social interaction 
(four items). An overall summary index score can also be cal-
culated (179).
Number of items. Sixteen items.
Response options/scale. Five- point Likert scales.
Recall period for items. Four weeks.
Cost to use. The license fee depends on whether the use is 
for a commercial or an academic study, on the number of times 
the measure is to be used, on the language requirements, and on 
whether the user manual is required.
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How to obtain. A license to access the questionnaire and 
user manual can be requested from Oxford University Innovation 
at https://innov ation.ox.ac.uk.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 to 4, with 4 denot-
ing most severe. Raw scale scores are then each converted to 
a metric from 0 to 100, in which 100 denotes the most severe 
(177). The summary index score is simply calculated as the sum of 
the three subscale scores and is also converted to a metric from 
0 to 100 (179).
Score interpretation. Subscale scores and the summary 
index score range from 0 (representing optimal foot health) to 100 
(representing worst foot health). Higher scores therefore represent 
worse foot health (177). There are no published normative data.
Respondent time to complete. Five to 10 minutes.
Administrative burden. Calculation of subscale scores 
takes less than 5 minutes per participant.
Translations/adaptations. The MOXFQ has been trans-
lated and culturally adapted into Chinese (180), Dutch (181), 
German (182), Italian (183), Korean (184), Persian (185), Span-
ish (186), and Turkish (187). Danish, Finnish, Welsh, Lithuanian, 
Norwegian, and French versions are also available from Oxford 
University Innovation.
Psychometric information
Floor and ceiling effects. In the original study, no items 
exhibited a ceiling effect, but 2 items on the 20- item scale exhib-
ited a floor effect and were therefore excluded from the final 16- 
item version (177). Subsequent studies using the 16- item scale 
have generally shown floor and ceiling effects of less than 15% 
(178,182,185,186,188). However, the Spanish version exhibited a 
20% ceiling effect for the walking/standing subscale because more 
than 50% of participants selected the highest score option for 
items 2 through 6 (186).
Reliability. Internal consistency (Cronbach’s α) in the orig-
inal study of 100 patients undergoing hallux valgus surgery for 
each subscale was as follows: walking/standing, 0.92; foot pain, 
0.86; and social interaction, 0.73 (177). Similar results were sub-
sequently observed in the translated versions, with the range of 
Cronbach’s α for each subscale as follows: walking/standing, 
0.77 to 0.99; pain, 0.78 to 0.98; and social interaction, 0.70 to 
0.99 (180–188). Test- retest reliability (intraclass correlation coeffi-
cients) in 257 patients undergoing various foot and ankle surgical 
procedures for each subscale has been reported as follows: walk-
ing/standing, 0.96; pain, 0.94; and social interaction, 0.92 (178). 
Across the various language translations, test- retest reliability has 
been reported as follows: walking/standing, 0.82 to 0.97; pain, 
0.81 to 0.98; and social interaction, 0.82 to 0.96 (180–188).
Validity. Content validity was originally examined by 
using exploratory, semistructured interviews conducted with 10 
patients who were attending hospital surgical outpatient clinics 
for hallux valgus, followed by patients completing and com-
menting on the MFPDI. This resulted in the rewording of some 
MFPDI items, the addition of two items specifically addressing 
pain severity and pain frequency at nighttime, and the increasing 
of the response categories from three to five per item (177). Crite-
rion validity has not been evaluated because of the absence of a 
gold standard measure of foot pain or function. Construct validity 
has been demonstrated by the observation of moderate asso-
ciations (Spearman’s ρ) between MOXFQ subscale scores and 
the AOFAS score (walking/standing, 0.47- 0.56; pain, 0.37- 0.60; 
and social interaction, 0.29- 48) (177,186,188); the SF- 36 physi-
cal functioning (walking/standing, 0.53- 73; pain, 0.39- 0.66; and 
social interaction, 0.31- 0.68), role physical (walking/standing, 
0.30- 0.64; pain, 0.35- 0.66; and social interaction, 0.31- 0.63), 
and bodily pain (walking/standing, 0.32- 0.71; pain, 0.36- 0.69; 
and social interaction, 0.27- 0.70) subscales (180–188); the FFI 
(walking/standing, 0.70; pain, 0.71; and social interaction, 0.43) 
(180); and the EuroQOL 5D (walking/standing, 0.70; pain, 0.71; 
and social interaction, 0.63) (180).
Responsiveness. In the original validation sample of 100 
patients undergoing hallux valgus surgery, responsiveness at 
12 months (calculated by using effect sizes) was as follows: walk-
ing/standing, 1.12; pain, 1.57; and social interaction, 1.52 (177). 
More recently, similar responsiveness at 6 to 12 months has been 
reported in patients undergoing a range of foot and ankle surgical 
procedures: walking/standing, 0.86 to 2.60; pain, 1.10 to 2.30; 
and social interaction, 0.80 to 2.10 (186,188–190).
Minimally important differences. Minimally impor-
tant differences in 91 patients undergoing hallux valgus surgery 
have been reported for each of the subscales as follows: walk-
ing/standing, 16 points; pain, 12 points; and social interaction, 
24 points (25). In 671 patients undergoing a range of foot and 
ankle surgical procedures, minimally important differences were 
reported as follows: walking/standing, 16 points; pain, 10 points; 
and social interaction, 9 points (191).
Generalizability. Although the original MOXFQ was 
focused on evaluating the outcomes of hallux valgus surgery 
(177), it has also been found to be a useful outcome measure for 
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other types of foot surgery (178,188). Its application in nonsurgical 
studies, however, has not been as thoroughly examined.
Use in clinical trials. The MOXFQ has been used as an 
outcome measure in clinical trials of various injection therapies for 
neuroma (192) and plantar heel pain (193,194), in clinical trials of 
bracing for ankle fracture (195), and in clinical trials of surgery for 
hallux valgus (40) and ankle osteoarthritis (196).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the MOXFQ include its cov-
erage of three distinct domains of foot health (walking/stand-
ing, pain, and social interaction), its extensive psychometric 
evaluation, its availability in several languages, its high test- 
retest reliability and responsiveness, and ease of completion 
and scoring.
Caveats and cautions. The social interaction subscale 
does not perform as well as the walking/standing and pain sub-
scales in terms of internal consistency, test- retest reliability, and 
responsiveness. Footwear difficulties are limited to one item (“I feel 
self- conscious about the shoes I have to wear”), which may not 
reflect broader footwear issues related to foot problems.
Clinical usability. The MOXFQ is a feasible tool for use in 
clinical practice (189) and has been endorsed by the British Ortho-
paedic Foot and Ankle Society and the College of Podiatry (UK) as 
a standard instrument for assessing patient- reported outcomes 
after foot surgery (197). An analysis of readability has found that 
the MOXFQ is suitable for patients with at least fifth- grade level 
reading skills (139).
Research usability. The MOXFQ has been demonstrated 
to be an excellent tool for the evaluation of foot surgery outcomes, 
particularly hallux valgus, because it has a robust psychometric 
profile, has high test- retest reliability, and is highly responsive. Fur-
ther development is required to assess its performance in nonsur-
gical studies.
SELF- REPORTED FOOT AND ANKLE SCORE
Description
Purpose. The SEFAS is a patient- reported foot- and ankle- 
specific questionnaire adapted in 2012 (198) from the New Zea-
land Total Ankle Replacement Questionnaire (199), which was 
originally derived from the Oxford- 12 Total Hip Replacement 
Questionnaire (200).
Content or domains. The SEFAS questionnaire assesses 
different constructs, including pain, function, limitation of function, 
and other symptoms, that are not separated into domains (198).
Number of items. Twelve items.
Response options/scale. Five- point Likert scales: specific 
responses vary across items.
Recall period for items. Not stated.
Cost to use. Free.
How to obtain. The formatted questionnaire can be down-
loaded from http://www.sweda nkle.se/.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored from 0 to 4, in which 0 denotes 
the most severe and 4 denotes the least severe. Item scores are 
then summated to range between 0 and 48.
Score interpretation. The final score ranges between 0 
and 48, in which 0 represents the most severe disability and 48 
represents normal function (198). Age- and sex- specific norma-
tive data in 779 healthy people aged 20 to 89 years have been 
published (201).
Respondent time to complete. Three minutes (19).
Administrative burden. Calculation of the final score 
takes less than 5 minutes per participant.
Translations/adaptations. The SEFAS exists as an Eng-
lish and Swedish version (198). It has been adapted into German 
(202) and Norwegian (203) versions.
Psychometric information
Floor and ceiling effects. The SEFAS does not demon-
strate floor or ceiling effects. In the original study, the Swed-
ish SEFAS was administered to 135 individuals with ankle 
osteoarthritis undergoing ankle surgery and demonstrated no 
floor or ceiling effects (198). This was confirmed in a subsequent 
study of 118 individuals with forefoot disorders and 106 individu-
als with midfoot, hindfoot, and ankle disorders (204). These find-
ings have been supported for the German SEFAS (202).
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Reliability. In the original study using the Swedish SEFAS 
total score, internal consistency (Cronbach’s α) was evaluated in 
62 individuals with forefoot disorders and was 0.96 (198). Sim-
ilar findings were reported in a subsequent study of individuals 
with forefoot and midfoot, hindfoot, and ankle disorders (Cron-
bach’s α = 0.84 and 0.86, respectively) (204).These findings were 
confirmed by using the German SEFAS total score (Cronbach’s 
α = 0.89) (202) and the Norwegian SEFAS total score (Cronbach’s 
α = 0.93) (203). Test- retest reliability (intraclass correlation coef-
ficients) of the SEFAS total score has been reported as follows: 
Swedish SEFAS, 0.92 to 0.93 (198,204); German SEFAS, 0.97 
(202); and Norwegian SEFAS, 0.93 (203).
Validity. Content validity was determined by asking a group 
of orthopedic surgeons, physical therapists, and nurses, as well 
as 10 patients, to review the items and provide feedback, includ-
ing the need to revise, exclude, or add items. Minor revisions 
were made to the items; no items were excluded or added. A 
separate group of 40 patients with forefoot disorders were then 
asked to rate the importance of each item from a scale of 1 to 
3, in which 1 represented an unimportant item, 2 represented 
an important item, and 3 represented a highly important item. 
Items with a mean score of 2 or greater were considered rele-
vant. Item scores ranged from 2.0 to 2.8 (mean score 2.6), indi-
cating good construct validity (204). Criterion validity has not been 
examined because of the absence of a gold standard measure of 
foot and ankle pain and function. Construct (convergent) validity 
has been demonstrated by the observation of moderate associ-
ations (greater than or equal to 0.4; Spearman’s ρ or Pearson’s 
r) between the SEFAS total score and several outcome meas-
ures. The SEFAS total score has a moderate association with 
domains of FAOS: pain, 0.82 to 0.83; other symptoms, 0.50 to 
0.70; activities of daily living, 0.68 to 0.77; sport and recreational 
activities, 0.42 to 0.62; and quality of life, 0.67 to 0.82 (198,204). 
Moderate associations have been found for the MOXFQ walk-
ing/standing problems (0.73), pain (0.73), and issues related to 
social interaction (0.57) domains and the summary score (0.77) 
(188). Moderate associations have been found for the SF- 36 
physical functioning (0.64- 0.72), role physical (0.30- 0.44), bodily 
pain (0.71- 0.76), vitality (0.46- 0.52), and social functioning (0.39- 
0.51) domains and the physical component summary score (0.51) 
(198,204). Finally, moderate associations have been found for the 
EuroQOL 5D index score (0.53- 0.76) and the VAS score (0.41- 
0.65) (198,204).
Responsiveness. Responsiveness (6 months, calculated 
with the effect size and SRM) of the Swedish SEFAS total score 
was evaluated in 35 individuals with ankle osteoarthritis under-
going replacement or fusion and was 1.44 and 1.00, respec-
tively (198). Additionally, the responsiveness (6 months) of the 
Swedish SEFAS was evaluated in 66 individuals with forefoot 
disorders and 70 individuals with midfoot, hindfoot, and ankle 
disorders undergoing surgery (204). The effect size and SRM 
were 1.29 and 1.27, respectively, for the forefoot disorders 
group and 1.05 and 0.99, respectively, for the midfoot, hindfoot, 
and ankle disorders group. Responsiveness (6 months) of the 
German SEFAS total score was determined by using 177 indi-
viduals undergoing foot and/or ankle surgery for musculoskeletal 
disorders, and lower responsiveness was reported (effect size 
0.71; SRM 0.65) (202).
Minimally important differences. The minimally impor-
tant difference for the Swedish SEFAS calculated in 163 patients 
undergoing a range of foot and ankle surgical procedures by using 
an anchor- based approach has been reported to be 5 points 
(205).
Generalizability. The SEFAS was originally developed and 
validated in individuals undergoing total replacement or fusion sur-
gery for disorders of the ankle (198), but its psychometric prop-
erties have also been evaluated in individuals undergoing foot 
surgery (188,202,204). Its application in nonsurgical studies has 
not been rigorously examined.
Use in clinical trials. The SEFAS has not been used in any 
randomized trials. However, it has been used in studies investigat-
ing clinical improvement following surgery for hallux valgus (206), 
posterior tibial tendon dysfunction (207), ankle joint disorders 
(208), and ankle fractures (209,210) as well as studies investigat-
ing clinical improvement following ankle fusion and replacement 
(211). The SEFAS has also been used in studies evaluating clinical 
improvement following corticosteroid injection for midfoot osteo-
arthritis (212).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the SEFAS include it being 
designed for a range of foot and ankle disorders; it being freely 
available, fast to administer, and easy to score; its substantial psy-
chometric evaluation (by using the total score rather than separate 
domains); and its availability in several languages.
Caveats and cautions. The SEFAS questionnaire assesses 
different constructs, including pain, function, limitation of function, 
and other symptoms, but these were not separated into domains 
when it was originally developed, and a psychometric evaluation 
of these domains was not performed (198,204). Psychometric 
evaluation has not occurred for the English version of the SEFAS. 
Further psychometric evaluation has primarily occurred in individ-
uals awaiting foot and/or ankle surgery, so the generalizability is 
limited. Finally, a Rasch analysis has not yet been undertaken.
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Clinical usability. The SEFAS is a feasible outcome for 
use in clinical practice. It is simple and efficient to administer and 
score. However, a significant limitation is that the items that con-
tribute to its domains were not clearly defined when it was origi-
nally developed.
Research usability. The psychometric properties of the 
English SEFAS requires further investigation. Additionally, although 
the total score of the SEFAS (non- English) has undergone sub-
stantial psychometric evaluation, the psychometric properties of 
its domains have not been evaluated.
VISUAL ANALOG SCALE–FOOT AND ANKLE
Description
Purpose. The VAS- FA was developed in 2006 to evaluate 
the effectiveness of surgical and nonsurgical interventions for foot 
and ankle disorders (213).
Content or domains. The VAS- FA questionnaire assesses 
three domains: pain (4 items), function (11 items), and other com-
plaints (5 items) (213).
Number of items. Twenty items.
Response options/scale. VAS (0- 100 mm).
Recall period for items. The wording of the items does 
not specify a recall period. However, participants can be provided 
with instructions to respond to the items referring to one of three 
options: 1) the period before the accident/surgery, 2) the period 
between the accident/surgery and implant removal, or 3) the 
period since implant removal.
Cost to use. Free.
How to obtain. The VAS- FA instructions and score form 
can downloaded from https://www.krank enhaus-rumme lsberg.
de/fuss-und-sprun ggele nkchi rurgi e/spezi elle-metho den-impla 
ntate/ visual-analog-skala-fuss-und-sprun ggele nk-vas-fa/.
Practical application
Method of administration. Self- administered with paper 
and pencil.
Scoring. Each item is scored by using a VAS that ranges from 
0 to 100, in which 0 denotes the most severe and 100 denotes 
the least severe. The scores from each item are summated, and 
this value is then divided by 20, resulting in a possible total score 
ranging from 0 to 100. To obtain scores for each domain, the 
summated scores for the items that make up each domain (pain, 
4 items; function, 11 items; other complaints, 5 items) are divided 
by the number of items for that domain. When there are missing 
responses to items, the developers recommend dividing the sum-
mated score by the number of remaining items (213).
Score interpretation. The total score ranges from 0 to 
100. Each domain score also ranges from 0 to 100. A score of 
0 (for the total score or each domain) represents the most severe 
state, and 100 represents the least severe state. Normative data 
from 121 healthy individuals have been published (214).
Respondent time to complete. Respondent time to 
complete is reported to range from 20 seconds to 6 minutes 
(213,215).
Administrative burden. Thirty seconds when using the 
evaluation matrix provided on the website (213).
Translations/adaptations. The VAS- FA was originally 
presented as a German version with the English translation pro-
vided (213) and has subsequently been translated and culturally 
adapted into Finnish (216), Indian (Malayalam language) (217), 
Thai (215), and Turkish (218).
Psychometric information
Floor and ceiling effects. No floor or ceiling effects have 
been reported for the total score of the Thai VAS- FA (215) or the 
total and domain scores of the Finnish VAS- FA (216). However, 
several items within each domain (Finnish VAS- FA) have been 
reported to demonstrate ceiling effects (216).
Reliability. Internal consistency (Cronbach’s α) of the Thai 
VAS- FA has been reported for the total score as greater than 0.99. 
Additionally, internal consistency (Cronbach’s α) of the Turkish 
VAS- FA total and domain scores has been reported for individuals 
with foot pain (0.75- 0.92) and without foot pain (0.93- 0.96) (218). 
Finally, internal consistency (Cronbach’s α) of the Finnish VAS- FA 
total and domain scores was evaluated in 165 individuals who had 
undergone foot and/or ankle surgery and was reported as follows: 
total, 0.96; pain, 0.91; function, 0.94; and other complaints, 0.81 
(216).
Test- retest reliability of the total score of the Thai VAS- FA in 
42 individuals has been reported as 0.99 (95% confidence interval 
[CI] 0.99- 1.00) (215). In addition, test- retest reliability (intraclass 
correlation coefficients) of the Turkish VAS- FA in 128 individuals 
(63 with foot disorders and 65 asymptomatic individuals) for the 
total score and each domain score has been reported as follows: 
total, 0.93 (95% CI 0.90- 0.96); pain, 0.88 (95% CI 0.819- 0.928); 
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function, 0.88 (95% CI 0.82- 0.93); and other, 0.93 (95% CI 0.90- 
0.96) (218). Similarly, test- retest reliability (intraclass correlation 
coefficients) of the total score of the Finnish VAS- FA was 0.93 
(216).
Validity. Content validity was not examined in the original 
study (213). Criterion validity has not been determined because 
of the absence of a gold standard measure of foot and ankle pain 
and function. Construct validity has been demonstrated by the 
observation of moderate associations (greater than or equal to 
0.4; Spearman’s ρ or Pearson’s r) between the German VAS- FA 
total score and the SF- 36 domain scores: overall, 0.6; pain, 0.5; 
function, 0.6; and other complaints, 0.5 (213). Similarly, associa-
tions of varying magnitude have been shown between the Thai 
VAS- FA total score and SF- 36 domain scores, with stronger rela-
tionships for the physical component summary score (physical 
functioning, 0.55; role physical, 0.60; bodily pain, 0.61; general 
health, 0.37) than the mental component summary score (vitality, 
0.22; social functioning, 0.36; role emotional, 0.35; and mental 
health, 0.18), suggestive of good convergent and divergent validity 
(215). Associations (Pearson’s r) between the Turkish VAS- FA total 
and domain scores and the SF- 36 (total, 0.34- 0.55; pain, 0.03- 
0.52; function, 0.27- 0.32) have been reported in individuals with 
and without foot pain (218). Supporting these findings, the Finn-
ish VAS- FA total and domain scores have been reported to have 
associations (Spearman’s ρ or Pearson’s r) with the total score 
and dimensions of the 15- Dimensional Health- Related Quality of 
Life Questionnaire, particularly the dimensions of mobility, usual 
activities, discomfort and symptoms, and vitality (216,219).
Associations (Pearson’s r) between the Turkish VAS- FA total 
and domain scores with the FFI (total, 0.40- 0.51; pain, 0.47- 0.48; 
function, 0.05- 0.53) and FAOS (total, 0.50- 0.55; pain, 0.47- 0.54; 
function, 0.34- 0.37; other complaints, 0.19- 0.28) have been 
reported for individuals with and without foot pain (218). Sup-
porting these findings, the Finnish VAS- FA total score has been 
reported to have a strong association (Spearman’s ρ) with the 
Lower Extremity Functional Scale (0.86) and the Western Ontario 
and McMaster Universities Osteoarthritis Index total score and 
subscales (0.75- 0.84) (216,219,220).
Responsiveness. Responsiveness of the VAS- FA has not 
been reported.
Minimally important differences. The minimally impor-
tant difference values for the VAS- FA total score or domains have 
not been reported.
Generalizability. The VAS- FA has broad generalizability. It 
was originally developed to be used to evaluate the effectiveness of 
surgical and nonsurgical interventions for foot and ankle disorders 
(213). Its psychometric properties have been evaluated in individ-
uals with a range of osseous (eg, infection, tumors, fractures, and 
osteoarthritis) (216–219) and soft tissue (eg, nonspecific arthritis, 
plantar fasciitis, tarsal tunnel syndrome, tenosynovitis, bursitis, 
and ankle sprains) disorders of the foot and ankle (218).
Use in clinical trials. The VAS- FA has been used in a 
limited number of randomized trials. These trials include the 
evaluation of active controlled movement in individuals after 
surgery for unstable ankle fracture (221), endoscopic versus 
open excision of symptomatic os trigonum for posterior ankle 
impingement syndrome (222), intraoperative pedobarography 
for individuals undergoing foot and/or ankle surgery (223), and 
extracorporeal shockwave therapy for insertional Achilles tendi-
nopathy (224).
Critical appraisal of overall value to the  
rheumatology community
Strengths. Key strengths of the VAS- FA include its broad 
generalizability, its inclusion of two key distinct domains of foot 
health (pain and function), it being freely available and relatively 
quick to administer and score, its availability in several languages, 
its excellent reliability, and its substantial construct validity.
Caveats and cautions. The VAS- FA was originally 
described by using asymptomatic individuals. Content validity has 
not been evaluated. The VAS- FA is most weighted for the function 
domain (11 items) relative to the other domains of pain and other 
complaints (4 and 5 items, respectively). The responsiveness 
and minimally important difference values have not been reported. 
Finally, a Rasch analysis has not yet been undertaken.
Clinical usability. The VAS- FA is a feasible outcome for 
use in clinical practice. It is simple and quick to administer and 
score. The scoring system accommodates for missing values.
Research usability. Although the VAS- FA has undergone 
substantial psychometric evaluation for its construct validity, its 
content validity, its responsiveness, and the minimally important 
difference values require evaluation.
CONCLUSIONS
This review has outlined the most frequently used patient- 
reported outcome measures that evaluate pain, function, and 
general health for people with foot and ankle conditions. Table 1 
provides a summary of the practical application of each patient- 
reported outcome measure, and Table 2 outlines the psychomet-
ric properties of each patient- reported outcome measure. The 
outcome measures reviewed have undergone varying degrees of 
psychometric validation, and each has advantages and disadvan-
tages. The selection of the most appropriate measure is therefore 
dependent on the context (ie, clinical or research use), the condi-
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tion and population being evaluated, and the usability/accepta-
bility to patients or research participants.
Based on our evaluation of the literature, we recommend 
the use of the FFI- R, FHSQ, or MOXFQ for clinical trials of gen-
eral foot disorders; the FAAM for sports- related ankle conditions; 
the LFIS for inflammatory disorders; and the MOXFQ or SEFAS 
for foot surgery. The MFPDI appears to be better suited to popu-
lation surveys than clinical trials, and both the FAOS and VAS- FA 
require more psychometric development (specifically calculation 
of minimally important difference values and responsiveness and 
a Rasch analysis) before they can be recommended for research 
use. Despite being widely used, the AOFAS advises against 
using the AOFAS scales because of questionable validity and 
reliability.
Further research is required to improve the performance of 
foot and ankle outcome measures in both clinical practice and 
research settings. Specifically, many of these measures lack 
population- based normative data or minimally important differ-
ences, few have undergone Rasch analysis, and few have been 
validated in populations beyond the initial validation studies. 
Addressing these shortcomings will help optimize the assessment 
and management of individuals with musculoskeletal foot disor-
ders.
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m
 to
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gh
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ho
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 c
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et
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el
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cr
ite
rio
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o;
 
co
ns
tr
uc
t: 
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s
Pa
in
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er
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hi
gh
; f
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 fo
ot
w
ea
r: 
lo
w
; 
ge
ne
ra
l f
oo
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ea
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er
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in
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1-
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fu
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tio
n:
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ot
w
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ne
ra
l f
oo
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al
th
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 c
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ow
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st
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o;
 
co
ns
tr
uc
t: 
ye
s
M
od
er
at
e
U
nk
no
w
n
Rh
eu
m
at
oi
d 
ar
th
rit
is
Li
m
ite
d
M
FP
D
I
N
o
In
te
rn
al
 c
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le
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rio
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uc
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ns
ity
: s
m
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pe
ar
an
ce
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U
nk
no
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oa
d
Li
m
ite
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O
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te
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 c
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si
st
en
cy
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ex
ce
lle
nt
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es
t- r
et
es
t: 
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ce
lle
nt
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nt
en
t: 
ye
s;
 
cr
ite
rio
n:
 n
o;
 
co
ns
tr
uc
t: 
ye
s
W
al
ki
ng
/s
ta
nd
in
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m
od
er
at
e 
to
 v
er
y 
hi
gh
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er
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hi
gh
; s
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ia
l 
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ra
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 v
er
y 
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gh
W
al
ki
ng
/
st
an
di
ng
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 p
ai
n:
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ia
l 
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ra
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n:
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Pr
ed
om
in
an
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 s
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gi
ca
l
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m
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d
SE
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S
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te
rn
al
 c
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si
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en
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ce
lle
nt
; t
es
t- r
et
es
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ce
lle
nt
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nt
en
t: 
ye
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cr
ite
rio
n:
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s
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h
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ta
l s
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Pr
ed
om
in
an
tly
 s
ur
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ca
l
N
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e
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N
o
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te
rn
al
 c
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si
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en
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ce
lle
nt
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es
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et
es
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ce
lle
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nt
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; c
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; c
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AH
 =
 a
nk
le
/h
in
df
oo
t; 
AO
FA
S 
= 
Am
er
ic
an
 O
rt
ho
pa
ed
ic
 F
oo
t a
nd
 A
nk
le
 S
oc
ie
ty
; F
AA
M
 =
 F
oo
t a
nd
 A
nk
le
 A
bi
lit
y 
M
ea
su
re
; F
AO
S 
= 
Fo
ot
 a
nd
 A
nk
le
 O
ut
co
m
e 
Sc
or
e;
 F
FI
- R
 =
 F
oo
t F
un
ct
io
n 
In
de
x–
Re
vi
se
d;
 F
H
SQ
 =
 F
oo
t H
ea
lth
 S
ta
tu
s 
Q
ue
st
io
nn
ai
re
; L
FI
S-
 RA
 =
 L
ee
ds
 F
oo
t I
m
pa
ct
 S
ca
le
 fo
r 
Rh
eu
m
at
oi
d 
Ar
th
rit
is
; L
J =
 le
ss
er
 m
et
at
ar
so
ph
al
an
ge
al
- in
te
rp
ha
la
ng
ea
l; 
M
 =
 m
id
fo
ot
; M
FP
D
I =
 
M
an
ch
es
te
r 
Fo
ot
 P
ai
n 
an
d 
D
is
ab
ili
ty
 In
de
x;
 M
O
XF
Q
 =
 M
an
ch
es
te
r-
 O
xf
or
d 
Fo
ot
 Q
ue
st
io
nn
ai
re
; R
CT
 =
 r
an
do
m
 c
on
tr
ol
le
d 
tr
ia
l; 
SE
FA
S 
= 
Se
lf-
 Re
po
rt
ed
 F
oo
t a
nd
 A
nk
le
 S
co
re
; V
AS
- F
A 
= 
Vi
su
al
 
An
al
og
 S
ca
le
–F
oo
t a
nd
 A
nk
le
.
† 
D
es
cr
ip
to
rs
 b
as
ed
 o
n 
th
e 
fo
llo
w
in
g 
sc
al
e,
 ir
re
sp
ec
tiv
e 
of
 re
lia
bi
lit
y 
st
at
is
tic
s 
us
ed
: p
oo
r (
<0
.4
0)
, f
ai
r (
0.
40
- 0
.5
9)
, g
oo
d 
(0
.6
0-
 0.
74
), 
an
d 
ex
ce
lle
nt
 (0
.7
5-
 1.
00
). 
‡ 
D
es
cr
ip
to
rs
 b
as
ed
 o
n 
an
 a
gg
re
ga
te
 o
f t
he
 re
sp
on
si
ve
ne
ss
 s
ta
tis
tic
s 
re
po
rt
ed
 fo
r e
ac
h 
m
ea
su
re
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